Literature DB >> 16679430

Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy.

G J D Hengstman1, H J ter Laak, W T M Vree Egberts, I E Lundberg, H M Moutsopoulos, J Vencovsky, A Doria, M Mosca, W J van Venrooij, B G M van Engelen.   

Abstract

OBJECTIVE: To elucidate the clinical importance of the anti-signal recognition particle (SRP) autoantibody in patients with myositis.
METHODS: Retrospective systematic assessment of the clinical, laboratory and histological characteristics of 23 anti-SRP-positive patients from six European centres. Data were compared with a large group of anti-SRP-negative patients with myositis published previously.
RESULTS: Clinically, patients with anti-SRP autoantibodies often had a severe symmetric proximal muscle weakness resulting in marked disability, dysphagia and highly elevated levels of serum creatine kinase. Three patients had typical dermatomyositis rashes. The disease was associated with the occurrence of extramuscular signs and symptoms including interstitial lung disease. No association was found with an increased risk of cardiac involvement, and the disease carried a reasonably favourable prognosis with most patients responding to treatment. None of the patients had the typical histological features of myositis. Most muscle biopsy specimens showed the presence of necrotic muscle fibres and no inflammatory infiltrates.
CONCLUSIONS: Anti-SRP autoantibodies are associated with a syndrome of a necrotising myopathy in the spectrum of immune-mediated myopathies that differs from typical polymyositis. Further studies are needed to elucidate the pathogenesis and to clarify the role of the anti-SRP autoantibodies in this unique disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16679430      PMCID: PMC1798474          DOI: 10.1136/ard.2006.052191

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  18 in total

1.  Autoantibody profiles in the sera of European patients with myositis.

Authors:  R Brouwer; G J Hengstman; W Vree Egberts; H Ehrfeld; B Bozic; A Ghirardello; G Grøndal; M Hietarinta; D Isenberg; J R Kalden; I Lundberg; H Moutsopoulos; P Roux-Lombard; J Vencovsky; A Wikman; H P Seelig; B G van Engelen ; W J van Venrooij
Journal:  Ann Rheum Dis       Date:  2001-02       Impact factor: 19.103

Review 2.  Interstitial lung disease in polymyositis and dermatomyositis.

Authors:  M Hirakata; S Nagai
Journal:  Curr Opin Rheumatol       Date:  2000-11       Impact factor: 5.006

3.  Frequency of relapses in patients with polymyositis and dermatomyositis.

Authors:  B A Phillips; P Zilko; M J Garlepp; F L Mastaglia
Journal:  Muscle Nerve       Date:  1998-12       Impact factor: 3.217

4.  Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies.

Authors:  I Hausmanowa-Petrusewicz; E Kowalska-Oledzka; F W Miller; M Jarzabek-Chorzelska; I N Targoff; M Blaszczyk-Kostanecka; S Jablonska
Journal:  Arthritis Rheum       Date:  1997-07

5.  Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies.

Authors:  G J D Hengstman; R Brouwer; W T M Vree Egberts; H P Seelig; P J H Jongen; W J van Venrooij; B G van Engelen
Journal:  J Neurol       Date:  2002-01       Impact factor: 4.849

6.  Myopathy with antibodies to the signal recognition particle: clinical and pathological features.

Authors:  T Miller; M T Al-Lozi; G Lopate; A Pestronk
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-10       Impact factor: 10.154

Review 7.  Polymyositis and dermatomyositis.

Authors:  Marinos C Dalakas; Reinhard Hohlfeld
Journal:  Lancet       Date:  2003-09-20       Impact factor: 79.321

8.  Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy.

Authors:  Amy H Kao; David Lacomis; Mary Lucas; Noreen Fertig; Chester V Oddis
Journal:  Arthritis Rheum       Date:  2004-01

Review 9.  Iatrogenic and toxic myopathies.

Authors:  Joern P Sieb; Thomas Gillessen
Journal:  Muscle Nerve       Date:  2003-02       Impact factor: 3.217

10.  Diagnostic value of MHC class I staining in idiopathic inflammatory myopathies.

Authors:  J van der Pas; G J D Hengstman; H J ter Laak; G F Borm; B G M van Engelen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-01       Impact factor: 10.154

View more
  80 in total

1.  Interstitial Lung Disease in Idiopathic Inflammatory Myopathy.

Authors:  Lesley Ann Saketkoo; Dana P Ascherman; Vincent Cottin; Lisa Christopher-Stine; Sonye K Danoff; Chester V Oddis
Journal:  Curr Rheumatol Rev       Date:  2010-05

2.  A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy.

Authors:  Lisa Christopher-Stine; Livia A Casciola-Rosen; Grace Hong; Tae Chung; Andrea M Corse; Andrew L Mammen
Journal:  Arthritis Rheum       Date:  2010-09

3.  Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series.

Authors:  Ritu Valiyil; Livia Casciola-Rosen; Grace Hong; Andrew Mammen; Lisa Christopher-Stine
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-09       Impact factor: 4.794

Review 4.  Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.

Authors:  Jian-Qiang Wu; Mei-Ping Lu; Ann M Reed
Journal:  World J Pediatr       Date:  2019-09-26       Impact factor: 2.764

Review 5.  Myositis-specific autoantibodies: detection and clinical associations.

Authors:  Sander H J van Dooren; Walther J van Venrooij; Ger J M Pruijn
Journal:  Auto Immun Highlights       Date:  2011-03-23

Review 6.  Review of the "X chromosome-nucleolus nexus" hypothesis of autoimmune diseases with an update explaining disruption of the nucleolus.

Authors:  Wesley H Brooks
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

Review 7.  Calcinosis and malignancy are rare in Chinese adult patients with myositis and nuclear matrix protein 2 antibodies identified by an unlabeled immunoprecipitation assay.

Authors:  Li Wang; Li Huang; Yang Yang; Huan Chen; Yanjuan Liu; Ke Liu; Meidong Liu; Yizhi Xiao; Hui Luo; Xiaoxia Zuo; Yisha Li; Xianzhong Xiao; Huali Zhang
Journal:  Clin Rheumatol       Date:  2018-07-23       Impact factor: 2.980

Review 8.  Potential Pathogenic Role of Anti-Signal Recognition Protein and Anti-3-hydroxy-3-methylglutaryl-CoA Reductase Antibodies in Immune-Mediated Necrotizing Myopathies.

Authors:  Leandro Ladislau; Louiza Arouche-Delaperche; Yves Allenbach; Olivier Benveniste
Journal:  Curr Rheumatol Rep       Date:  2018-08-03       Impact factor: 4.592

9.  Autoantibodies and their significance in myositis.

Authors:  Ira N Targoff
Journal:  Curr Rheumatol Rep       Date:  2008-08       Impact factor: 4.592

10.  Myocardial involvement in idiopathic inflammatory myopathies: a multi-center cross-sectional study in the CRDC-MYO Registry.

Authors:  Lixi Zhang; Huiyi Zhu; Pinting Yang; Xinwang Duan; Wei Wei; Zhenbiao Wu; Yongfei Fang; Qin Li; Shengyun Liu; Xiaofei Shi; Hongbin Li; Chanyuan Wu; Shuang Zhou; Xiaomei Leng; Jiuliang Zhao; Dong Xu; Qingjun Wu; Xinping Tian; Mengtao Li; Yan Zhao; Qian Wang; Xiaofeng Zeng
Journal:  Clin Rheumatol       Date:  2021-06-29       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.